Next Article in Journal
Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System
Previous Article in Journal
Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies
Article Menu

Export Article

Open AccessCase Report
J. Pers. Med. 2012, 2(3), 71-76; doi:10.3390/jpm2030071

Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report

1
Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA
2
Department of Surgery, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA
3
Department of Womens Health, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA
*
Author to whom correspondence should be addressed.
Received: 16 August 2012 / Accepted: 4 September 2012 / Published: 10 September 2012
View Full-Text   |   Download PDF [647 KB, uploaded 10 September 2012]   |  

Abstract

Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient’s decision. In light of this case, we discuss the benefits and limitations of these tools.
Keywords: breast cancer; genomic profiling; medical decision-making; Oncotype DX; chemotherapy; personalized medicine breast cancer; genomic profiling; medical decision-making; Oncotype DX; chemotherapy; personalized medicine
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schuster, S.R.; Pockaj, B.A.; Bothe, M.R.; David, P.S.; Northfelt, D.W. Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report. J. Pers. Med. 2012, 2, 71-76.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top